Related references
Note: Only part of the references are listed.The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
Domenico De Berardis et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2011)
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response
Alan G. Wade et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
A Closer Look at the High Affinity Benzodiazepine Binding Site on GABA(A) Receptors
Erwin Sigel et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Tasimelteon for insomnia
D. Alan Lankford
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study
Naohisa Uchimura et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance
Susan L. McElroy et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2011)
Melatonin has membrane receptor-independent hypnotic action on neurons: an hypothesis
James E. Jan et al.
JOURNAL OF PINEAL RESEARCH (2011)
Insomnia: Neurophysiological and NeuropsychologicalApproaches
Celyne H. Bastien
NEUROPSYCHOLOGY REVIEW (2011)
Melatonin-A pleiotropic, orchestrating regulator molecule
Ruediger Hardeland et al.
PROGRESS IN NEUROBIOLOGY (2011)
Long-term safety and efficacy of ramelteon in Japanese patients with chronic insomnia
Makoto Uchiyama et al.
SLEEP MEDICINE (2011)
Jet Lag, Circadian Rhythm Sleep Disturbances, and Depression: the Role of Melatonin and its Analogs
Venkatramanujam Srinivasan et al.
ADVANCES IN THERAPY (2010)
Aquaporin-1 in blood vessels of rat circumventricular organs
Alan J. Wilson et al.
CELL AND TISSUE RESEARCH (2010)
Agomelatine in the Treatment of Major Depressive Disorder Potential for Clinical Effectiveness
Sidney H. Kennedy et al.
CNS DRUGS (2010)
Metabolism of Benzodiazepine and Non-Benzodiazepine Anxiolytic-Hypnotic Drugs: an Analytical Point of View
Roberto Mandrioli et al.
CURRENT DRUG METABOLISM (2010)
Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline
Siegfried Kasper et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission
Pierre-Michel Llorca
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders
S. J. Wilson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development (vol 9, pg 628, 2010)
Christian de Bodinat et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors
Margarita L. Dubocovich et al.
PHARMACOLOGICAL REVIEWS (2010)
Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial
Els I. S. Most et al.
TRIALS (2010)
Ramelteon: a review of its therapeutic potential in sleep disorders
Seithikurippu R. Pandi-Perumal et al.
ADVANCES IN THERAPY (2009)
The role of eszopiclone in the treatment of insomnia
Anna K. Morin et al.
ADVANCES IN THERAPY (2009)
Pharmacology of Ramelteon, a Selective MT1/MT2 Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders
Masaomi Miyamoto
CNS NEUROSCIENCE & THERAPEUTICS (2009)
Comparative Tolerability of Newer Agents for Insomnia
Gary Zammit
DRUG SAFETY (2009)
Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?
H. -P. Landolt et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Antidepressant-like effects of melatonin in the mouse chronic mild stress model
Bernardo C. Detanico et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Melatonin and Melatonergic Drugs on Sleep: Possible Mechanisms of Action
Venkataramanujan Srinivasan et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2009)
Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials
Shantha M. W. Rajaratnam et al.
LANCET (2009)
Zaleplon increases nocturnal melatonin secretion in humans
A. L. Morera et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
Efficacy and Safety of 6-Month Nightly Ramelteon Administration in Adults with Chronic Primary Insomnia
Geert Mayer et al.
SLEEP (2009)
Activation of 5-HT2C receptors acutely induces Per1 gene expression in the rat SCN in vitro
Tamara J. Varcoe et al.
BRAIN RESEARCH (2008)
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: Post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect
Louis Mini et al.
CLINICAL THERAPEUTICS (2008)
Eszopiclone - A review of its use in the treatment of insomnia
Philip I. Hair et al.
DRUGS (2008)
The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders
Seithikurippu R. Pandi-Perumal et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2008)
Non-REM sleep instability in patients with major depressive disorder: Subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine)
M. Cecilia Lopes et al.
SLEEP MEDICINE (2007)
Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects
Patrick Lemoine et al.
JOURNAL OF SLEEP RESEARCH (2007)
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine
Patrick Lemoine et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
Joseph R. Calabrese et al.
BIPOLAR DISORDERS (2007)
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia
Thomas Roth et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2
David J. Greenblatt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The brain's master circadian clock: Implications and opportunities for therapy of sleep disorders
Phyllis C. Zee et al.
SLEEP MEDICINE REVIEWS (2007)
The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease
Egemen Savaskan et al.
CURRENT ALZHEIMER RESEARCH (2007)
Sleep and circadian rhythms in mood disorders
R. Armitage
ACTA PSYCHIATRICA SCANDINAVICA (2007)
Melatonin modulates spike coding in the rat suprachiasmatic nucleus
A. N. Inyushkin et al.
JOURNAL OF NEUROENDOCRINOLOGY (2007)
Drug insight: the use of melatonergic agonists for the treatment of insomnia - focus on ramelteon
Seithikurippu R. Pandi-Perumal et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone
Ying-Hui Wu et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2006)
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model
Valerie Bertaina-Anglade et al.
BEHAVIOURAL PHARMACOLOGY (2006)
Reduced oxidative damage in ALS by high-dose enteral melatonin treatment
Jochen H. Weishaupt et al.
JOURNAL OF PINEAL RESEARCH (2006)
Depression and associated steep disturbances: patient benefits with agomelatine
David J. Kupfer
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
Recent developments in the classification, evaluation, and treatment of insomnia
Michael O. Summers et al.
CHEST (2006)
Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta):: Dependence liability studies
Charles P. France et al.
BEHAVIORAL NEUROSCIENCE (2006)
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia
Thomas Roth et al.
SLEEP MEDICINE (2006)
Sleep-anticipating effects of melatonin in the human brain
Tali Gorfine et al.
NEUROIMAGE (2006)
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
MJ Millan
PHARMACOLOGY & THERAPEUTICS (2006)
Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis
N Buscemi et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Sleep disturbances and depression: a challenge for antidepressants
RW Lam
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
SH Kennedy et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system
E Fuchs et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Agomelatine - A preliminary review of a new antidepressant
Michael Zupancic et al.
CNS DRUGS (2006)
A network of (Autonomic) clock outputs
A. Kalsbeek et al.
CHRONOBIOLOGY INTERNATIONAL (2006)
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia
M Erman et al.
SLEEP MEDICINE (2006)
Hypothalamic regulation of sleep and circadian rhythms
CB Saper et al.
NATURE (2005)
The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia:: A randomized, placebo-controlled, crossover clinical trial
FP Zemlan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
The hypothalamic integrator for circadian rhythms
CB Saper et al.
TRENDS IN NEUROSCIENCES (2005)
Long-term use of sedative hypnotics in older patients with insomnia
S Ancoli-Israel et al.
SLEEP MEDICINE (2005)
Effects of exogenous melatonin on sleep: a meta-analysis
A Brzezinski et al.
SLEEP MEDICINE REVIEWS (2005)
Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
K Kato et al.
NEUROPHARMACOLOGY (2005)
Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease
E Savaskan et al.
JOURNAL OF PINEAL RESEARCH (2005)
Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects.
S Stevenson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Study of the absorption, metabolism, and excretion of (14C)-ramelteon (TAK-375).
S Stevenson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
A systematic review of non-pharmacological therapies for sleep problems in later life
P Montgomery et al.
SLEEP MEDICINE REVIEWS (2004)
Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy
D Leger et al.
AMERICAN JOURNAL OF MEDICINE (2004)
A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, phannacokinetics and pharmaeodynamics of the melatonin analog β-methyl-6-chloromelatonin
JJ Mulchahey et al.
LIFE SCIENCES (2004)
Shift work sleep disorder: Prevalence and consequences beyond that of symptomatic day workers
CL Drake et al.
SLEEP (2004)
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
GK Zammit et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
N Yukuhiro et al.
BRAIN RESEARCH (2004)
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists
FW Turek et al.
SLEEP MEDICINE (2004)
Human circadian melatonin rhythm phase delay during a fixed sleep-wake schedule interspersed with nights of sleep deprivation
C Cajochen et al.
JOURNAL OF PINEAL RESEARCH (2003)
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
MJ Millan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist
NN Vachharajani et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia
AD Krystal et al.
SLEEP (2003)
Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement
J Montplaisir et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2003)
Melatonin microinjection into the medial preoptic area increases sleep in the rat
WB Mendelson
LIFE SCIENCES (2002)
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes
E Sanna et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients
E Savaskan et al.
JOURNAL OF PINEAL RESEARCH (2002)
Melatonin treatment for age-related insomnia
IV Zhdanova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
The impact of insomnia on cognitive functioning in older adults
M Cricco et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2001)
Circadian and sleep disturbances in the elderly
EJW Van Someren
EXPERIMENTAL GERONTOLOGY (2000)
Depression and insomnia: questions of cause and effect
L Lustberg et al.
SLEEP MEDICINE REVIEWS (2000)
Share Paper
